AustralianSuper’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
AustralianSuper's NBIX Position: Q3 2026 in Review
AustralianSuper reduced its Neurocrine Biosciences (NBIX) stake by 56% in Q3 2026, selling an estimated $31.4M and leaving 153,520 shares worth $21.8M. The position accounts for 0.09% of the portfolio, ranked #145.
AustralianSuper first reported a position in NBIX in Q4 2020 and has held it in 8 quarters since. The position peaked at $58.8M in Q2 2026. 683 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- AustralianSuper held 153,520 shares of Neurocrine Biosciences worth $21.8M as of Q3 2026.
- AustralianSuper sold 195,473 Neurocrine Biosciences shares in Q3 2026, an estimated $31.4M.
- Neurocrine Biosciences made up 0.09% of AustralianSuper's portfolio in Q3 2026, its #145 holding.
- AustralianSuper first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 8 quarters since.
- AustralianSuper's Neurocrine Biosciences position peaked at $58.8M in Q2 2026.
- 683 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on AustralianSuper's 13F filing for Q3 2026, filed 10 Nov 2026.